The essential thrombocythemia market is expected to grow steadily due to increasing disease prevalence, advancements in targeted therapies, and rising awareness. The development of JAK inhibitors and ...
Essential thrombocythemia is a myeloproliferative neoplasm with excessive platelet production, potentially causing clotting or bleeding issues. Diagnosis involves blood tests, genetic testing, and ...
Essential thrombocythemia (ET) is a rare condition affecting the bone marrow, resulting in an overproduction of platelets. It usually affects those over the age of 50, progresses slowly, and can be ...
Dear Dr. Gott: I have been diagnosed with essential thrombocytosis. I am being treated with hydroxyurea. I also experience leg cramps, neuropathy in my feet and a dropped left foot. I previously had ...
Some of the main goals of treatments for essential thrombocythemia include reducing disease progression and blood clots while improving symptom burden, but more treatments may be on the horizon ...
Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm (MPN) characterized by an increase in the number of platelets in the blood. Of the three main types of MPNs (ET, polycythemia ...
The predictive value of the MASCC score in patients with febrile neutropenia. Effects of various non-demographic variables on mortality and length of stay in stroke patients with history of ET.
The frequency of vascular events and evolution to myelofibrosis (MF) in young individuals with essential thrombocythemia (ET) is not well known. The incidence and predisposing factors to such ...
Beyond PEGASYS, the essential thrombocythemia treatment landscape is evolving with several promising assets in the pipeline. These include BESREMi (ropeginterferon alfa-2b), Bomedemstat ...
Findings showed 42.9% of P1101-treated patients achieved durable responses at both 9 and 12 months compared with 6% in those treated with anagrelide (P =.0001). Topline data were announced from a ...
Imetelstat, a 13-mer oligonucleotide that is covalently modified with lipid extensions, competitively inhibits telomerase enzymatic activity. It has been shown to inhibit megakaryocytic proliferation ...
We describe a patient with signs of partial third nerve palsy, severe iritis, and loss of vision due to essential thrombocytosis. A 60-year-old man was referred from the neurologists by whom he had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results